Drug Toxicity Clinical Trial
Official title:
Women's Hospital, Zhejiang University School of Medicine
In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with standard MTX single-drug multi-course regimen.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of gestational trophoblastic tumor; - Patients with prognosis score of 5 and 6 - Primary chemotherapy (preventive chemotherapy is not included); - Physical strength grade: Karnofsky score = 60; - WBC = 3.5× 109/L, ANC = 1.5× 109/L, PT = 80× 109/L, serum bilirubin = 1.5 times of normal high limit, transaminase = 1.5 times of normal high limit, BUN, Cr= normal; - Follow-up and good compliance; - Sign the informed consent form. Exclusion Criteria: - Pathological diagnosis is intermediate trophoblastic tumor, including PSTT and ETT; - There are serious or uncontrollable medical diseases, which are not suitable for chemotherapy; - Those who receive clinical trials of other drugs at the same time. - Those who receive Chinese medicine. |
Country | Name | City | State |
---|---|---|---|
China | Weiguo Lv | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Women's Hospital School Of Medicine Zhejiang University | Huazhong University of Science and Technology, Qilu Hospital of Shandong University, West China Second University Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | primary complete remission | complete remission rate by primary treatment | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
Recruiting |
NCT02306837 -
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
|
Phase 2 | |
Completed |
NCT02771470 -
Intestinal Microflora in Lung Cancer After Chemotherapy
|
Phase 1 | |
Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
Completed |
NCT02454673 -
Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Recruiting |
NCT02555592 -
Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
|
N/A | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Recruiting |
NCT02226380 -
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT00911352 -
Cryotherapy Intervention for Docetaxel-induced Nail Toxicities
|
Phase 2/Phase 3 | |
Completed |
NCT03840824 -
Blood Spot Self-administered Test and Assay
|
||
Active, not recruiting |
NCT01490060 -
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
|
N/A | |
Completed |
NCT02395341 -
The Longitudinal Ovarian Reserve Study
|
N/A | |
Recruiting |
NCT05268991 -
Aging and Frailty Study
|
||
Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
Enrolling by invitation |
NCT02074241 -
Molecular Markers of Chemosensitivity for Bladder Cancer
|
N/A | |
Completed |
NCT01143844 -
Assessing Fertility Potential in Female Cancer Survivors
|
||
Recruiting |
NCT02169388 -
Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy
|
Phase 1 | |
Completed |
NCT03402295 -
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
|
Phase 3 |